These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15810907)

  • 1. Prophylactic treatment effects on inhibitor risk: experience in one centre.
    Morado M; Villar A; Jiménez Yuste V; Quintana M; Hernandez Navarro F
    Haemophilia; 2005 Mar; 11(2):79-83. PubMed ID: 15810907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
    Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of prophylaxis treatment in children with severe haemophilia.
    Yee TT; Beeton K; Griffioen A; Harrington C; Miners A; Lee CA; Brown SA
    Haemophilia; 2002 Mar; 8(2):76-82. PubMed ID: 11952841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parachutes and prophylaxis: they both work!
    White GC
    J Thromb Haemost; 2006 Jun; 4(6):1226-7. PubMed ID: 16706964
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Various regimens for prophylactic treatment of patients with haemophilia.
    Schwarz R; Ljung R; Tedgård U
    Eur J Haematol; 2015 Feb; 94 Suppl 77():11-6. PubMed ID: 25560789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilia prophylaxis: a model and future directions in Jordan.
    Awidi A; Faouri S; Kiswani BA; Al-Sweedan S; Albarqawi M; Bsoul N; Haddadin I; Al-Falah M; Telfah A; Hermans C
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s343-4. PubMed ID: 24120588
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.
    Hilgartner MW; Makipernaa A; Dimichele DM
    Haemophilia; 2003 May; 9(3):261-8. PubMed ID: 12694515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of prophylaxis to prevent complications of hemophilia.
    Mannucci PM; Mendolicchio L; Gringeri A
    Adv Exp Med Biol; 2001; 489():59-64. PubMed ID: 11554591
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status of joint and intracranial bleeding of moderate and severe hemophilia in children under on-demand therapy].
    He WW; Wu RH
    Zhonghua Er Ke Za Zhi; 2012 Aug; 50(8):636-8. PubMed ID: 23158747
    [No Abstract]   [Full Text] [Related]  

  • 18. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE; Fischer K
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.